←
ViewMind427 posts
ViewMind avatar

ViewMind

@ViewMind_

Precision brain health. To help prevent, diagnose and personalize treatment for brain disorders.

◷ Joined April 2018▧ 73 Photos and videos
ViewMind avatar
ViewMind@ViewMind_·5 Aug 2025

Thank you to everyone who visited our stand and experienced ViewMind’s technology firsthand at the @alzassociation ’s International Conference in Toronto. linkedin.com/feed/update/urn… #AAIC2025 #BrainHealth #Alzheimers #ClinicalTrials #DigitalBiomarkers #Innovation

ViewMind avatar
ViewMind@ViewMind_·29 Jul 2025

We’ve just presented one of our new studies at AAIC 2025: “Cognitive and Motor Behaviors in Alzheimer’s, Parkinson’s, and Healthy Individuals.” Visit us at Booth #1437 to learn more about our cutting-edge cognitive assessment platform. #AAIC2025 @alzassociation

Post attachment
ViewMind avatar
ViewMind@ViewMind_·27 Jul 2025

We’re presenting 3 scientific posters, including: • Psychometric validation of ViewMind Atlas™ as a digital biomarker • Comparison with traditional neuropsychological tests • Cognitive & motor patterns in AD, Parkinson’s, and healthy individuals

ViewMind avatar
ViewMind@ViewMind_·27 Jul 2025

ViewMind Atlas™ is a non-invasive, eye-tracking-based digital tool that has the potential to support: ✔ Early detection of Alzheimer’s ✔ Cognitive endpoints in clinical trials ✔ Scalable integration into research and healthcare environments

ViewMind avatar
ViewMind@ViewMind_·31 Jan 2025

ALZHEIMER’S DRUG DISCOVERY FOUNDATION’S DIAGNOSTICS ACCELERATOR (DXA) Invests $1.4M in ViewMind’s technology. einpresswire.com/article/780… via @ein_news #BrainHealth #Alzheimers #NeurologicalDisorders #HealthTech #EyeTracking #InnovationInHealthcare #Biomarkers #PrecisionMedicine

ViewMind avatar
ViewMind@ViewMind_·23 Dec 2024

We look forward to continued collaboration in 2025 as we keep pushing the boundaries of cognitive health assessments. Thank you for being part of our journey. Wishing you all a peaceful holiday season and a successful new year.

ViewMind avatar
ViewMind@ViewMind_·17 Dec 2024

We appreciate the opportunity to contribute to discussions that drive innovation in brain health diagnostics.

ViewMind avatar
ViewMind@ViewMind_·17 Dec 2024

ViewMind’s non-invasive technology offers valuable insights that have the potential to also be relevant for endocrinologists. By detecting cognitive changes in cardiometabolic conditions, our solution has the potential to support earlier intervention and personalized care.

ViewMind avatar
ViewMind@ViewMind_·17 Dec 2024

His presentation, “Oculomotor Alterations and Cognitive Decline in Cardiometabolic Diseases – A New Diagnostic Modality?”, generated significant interest among specialists.

ViewMind avatar
ViewMind@ViewMind_·10 Dec 2024

"This advancement holds the potential to make a significant impact on healthcare. We are excited to participate in the landmark Bio-Hermes-002 study to validate our results,” said Mark Edwards, CEO & Co-founder of ViewMind Inc.

ViewMind avatar
ViewMind@ViewMind_·10 Dec 2024

"In addition, ViewMind has developed a specialized assessment for Alzheimer’s disease. Initial results indicate high sensitivity and specificity to detect asymptomatic stages over 10 years before symptoms and amnestic MCI. ” said Mark Edwards, CEO & Co-founder of ViewMind Inc.